PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
The user started oral finasteride in October 2025, switched to topical finasteride and minoxidil in mid-2026, and uses a dermastamp weekly. They are unsure about regrowth progress and feel insecure about their hairline.
A user shared their 8-year journey with hair loss treatments, including oral minoxidil, dutasteride, Propecia, and a 2500 FUT hair transplant, leading to significant hair regrowth and a healthy lifestyle. They experienced some side effects like oily skin and a higher-pitched voice but maintained high testosterone levels and a strong libido.
OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.
PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
A user shared progress pictures after almost 9 months of using oral finasteride (1 mg) and minoxidil (2.5 mg) for hair loss. They are optimistic about future results, and another user commented that it looks better.
A 24-year-old uses microneedling, tretinoin, topical and oral minoxidil, and oral finasteride for hair growth, noticing baby hair growth and initial side effects that resolved. Another user shares a similar regimen, excluding finasteride.
The user shared positive results after 5 months of using oral finasteride, reporting no side effects and continued shedding but less than in the initial months. Other users discussed their experiences with finasteride and minoxidil, with some expressing concerns about side effects and others sharing their own progress and plans.
A user's 14-month journey with finasteride, microneedling, and Nizoral to treat hair loss. They experienced some side effects such as ball ache, needing to pee constantly, and less semen, but the results were generally positive.
The conversation is about a product called FLEAVA, found in a Facebook ad, and whether it is effective or just another scam. One user believes it is likely a scam and mentions that such products usually don't compete with Minoxidil.
The user is excited about seeing new hair growth on their forehead after using finasteride, minoxidil, and microneedling for four months. Others caution that initial hair growth may not always lead to long-term results.
The conversation is about a user's hair growth progress after 9 months of using oral minoxidil and finasteride, along with dermastamping. The user reports improved hair health and color, with some visible scalp remaining, and no side effects from the treatment.
Finasteride maintains its efficacy over time, slowing hair loss but not completely stopping it. Long-term users often experience stability, though natural aging may cause gradual decline; additional treatments like minoxidil, RU58841, and others may be needed for aggressive hair loss.
The conversation is about a user running out of finasteride and seeking advice on alternatives or temporary solutions. Suggestions include trying different brands, using online prescribers, adjusting dosage, or considering a break from the medication.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
Homemade topical finasteride solutions are discussed, with one user using 30% ethanol, 50% propylene glycol, and 20% water. Alternatives like dissolving finasteride pills in minoxidil and using stemoxydine are also mentioned.
The user has been using finasteride (1 mg, three times a week) for a year and is considering adding oral minoxidil or increasing finasteride dosage, while also taking enclomiphene. They did not experience significant shedding with finasteride, but are concerned about potential shedding with new treatments.
The conversation discusses the potential long-term effects of stopping finasteride after extended use, with differing opinions on the existence and prevalence of post-finasteride syndrome (PFS). Some users report persistent side effects, while others argue that such effects are rare or unrelated to the medication.
A user shared progress pictures after 4 months of using oral Minoxidil and Finasteride, noting significant hair growth and some greying. Replies praised the results and inquired about the user's age, who is 33.
The user applied 0.005% topical finasteride, minoxidil, tretinoin, caffeine, and ketoconazole shampoo for four months but saw no hair regrowth. Some users suggested increasing the finasteride dose or trying alternative treatments like clascoterone, pyrilutamide, or RU58841.
A 34-year-old male reports significant hair regrowth progress after two months using oral finasteride (1.3mg) and minoxidil (3mg) chewable tablets, with no side effects. He plans to switch to a cheaper generic option.
DIM is suggested to help with estrogen metabolism for those on finasteride or dutasteride, potentially reversing side effects like fat gain and mood changes. Some users doubt its effectiveness, recommending lifestyle changes or consulting a doctor instead.
The user has been using finasteride 1 mg every other day for 9 months and oral minoxidil 2.5 mg for 5 months, noticing reduced shedding and healthier hair. They experienced mild side effects initially but report improvement and plan to grow their hair out to assess progress.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
The user is using topical finasteride (1MG in 30ML stemoxydine) and experiencing a lack of morning erections after three months. They are questioning whether to discontinue the treatment or if the side effect will resolve if they continue.
A user experienced increased estrogen levels after 11 months on finasteride, leading to concerns about feminizing effects. They plan to reduce the finasteride dosage and consider using an aromatase inhibitor to manage estrogen levels.
The conversation is about a user switching from finasteride to dutasteride after 4 years due to continued hair recession and miniaturization. The user plans to gradually increase to 1mg of dutasteride daily.